TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35958322

Group type: EXPERIMENTAL
Intervention: Anlotinib combined with epidermal growth factor receptor (EGFR) inhibitors in cohort A
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Anlotinib combined with EGFR inhibitors in cohort B
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (Cohort C)
Number of subjects: 82
Study: 35958344

Group type: EXPERIMENTAL
Intervention: Concurrent platinum-based chemoradiotherapy (CRT) followed by durvalumab maintenance treatment
Number of subjects: 40
Study: 35958398

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of aspirin (150 mg/day) in high-risk patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-trimester screening model using angiogenic markers (PlGF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate Gaussian distribution model for PE risk calculation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sFlt-1 values determination in high and intermediate risk patients
Number of subjects: 0
Study: 35958875

Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Empowerment
Number of subjects: 108
Study: 35959207

Group type: EXPERIMENTAL
Intervention: Dupilumab plus standard of care
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 40
Study: 35959564

Group type: COMPARATOR
Intervention: SBP < 160 mmHg in non-lacunar infarction group
Number of subjects: 1089

Group type: EXPERIMENTAL
Intervention: SBP ≥ 160 mmHg in non-lacunar infarction group
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Negative DWI
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Lacunar infarction
Number of subjects: 1089
Study: 35960137

Group type: EXPERIMENTAL
Intervention: 1-repetition maximum (1-RM) testing on a leg press
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cessation of testing after 1 failed attempt
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-RM testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple attempts at a failed load
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-RM test
Number of subjects: 0
Study: 35960332

Group type: EXPERIMENTAL
Intervention: Immunomodulatory five-drug cocktail (IDC) + Pembrolizumab + Radiotherapy (8Gyx3)
Number of subjects: 43
Study: 35960719

Group type: EXPERIMENTAL
Intervention: Higher adjusted respiratory rate
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Hospitalization/recurrent ED visits
Number of subjects: 1478
Study: 35961055

Group type: EXPERIMENTAL
Intervention: RSV episodes (nonhospitalized)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Influenza episodes (nonhospitalized)
Number of subjects: 1040
Study: 35961062

Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Syndrome (CTS) patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 75
Study: 35961260

Group type: EXPERIMENTAL
Intervention: PO lipids (2.5 g/kg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: PO glucose (2.5 g/kg)
Number of subjects: 65

Group type: COMPARATOR
Intervention: IV lipids (Intralipid/Liposyn II 20% at 0.35 ml/kg/h for 6 h)
Number of subjects: 65

Group type: COMPARATOR
Intervention: IV glucose (10% glucose at 3.6 ml/kg/h for 6 h)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Mixed Meal Test (MMT)
Number of subjects: 65
Study: 35961299

Group type: EXPERIMENTAL
Intervention: SalivaBio
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SaliPac
Number of subjects: 30

Group type: COMPARATOR
Intervention: Salivette
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive drool
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Storage at RT and 4 °C
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Repeated freeze-thaw cycles
Number of subjects: 30
Study: 35962206

Group type: EXPERIMENTAL
Intervention: Pralsetinib
Number of subjects: 29
Study: 35962320

Group type: EXPERIMENTAL
Intervention: SALT (Staphylococcus aureus Surgical Site Infection Multinational Epidemiology in Europe) coding system
Number of subjects: 15432

Group type: EXPERIMENTAL
Intervention: Mapping country-specific procedure codes
Number of subjects: 15432
Study: 35962339

Group type: EXPERIMENTAL
Intervention: three-month standard medical intervention to improve glycemic control
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control HDLs from healthy subjects carbamylated in vitro with potassium cyanate
Number of subjects: 27
Study: 35962368

Group type: EXPERIMENTAL
Intervention: Lithium carbonate orally achieving a serum level of 0.2-0.4 mmol/l between month 6 and 12
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 12
Study: 35962446

Group type: EXPERIMENTAL
Intervention: EQ5D
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: AFEQT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PACT-Q (part 2)
Number of subjects: 50
Study: 35962454

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Glucocorticoids (GCs)
Number of subjects: 122
Study: 35962459

Group type: EXPERIMENTAL
Intervention: AI-based model comprising imaging and clinical variables
Number of subjects: 1268

Group type: COMPARATOR
Intervention: Clinical models without imaging metrics
Number of subjects: 1268
Study: 35962841

Group type: EXPERIMENTAL
Intervention: Intraoperative measurements using the apex of the deep cartilage (ADC) as a landmark
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Postoperative measurements using 3D-CT
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Bland-Altman plot analysis
Number of subjects: 52
Study: 35962934

Group type: EXPERIMENTAL
Intervention: Acid-reducing agents (ARAs)
Number of subjects: 234

Group type: COMPARATOR
Intervention: Non-acid-reducing agents (non-ARA group)
Number of subjects: 234
Study: 35963263

Group type: EXPERIMENTAL
Intervention: GFAP
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: UCH-L1
Number of subjects: 1696

Group type: EXPERIMENTAL
Intervention: GFAP and UCH-L1 (combined)
Number of subjects: 1696
Study: 35963275

Group type: EXPERIMENTAL
Intervention: TB31F 1 mg/kg intravenous
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TB31F 3 mg/kg intravenous
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TB31F 10 mg/kg intravenous
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TB31F (all doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: TB31F serum concentration
Number of subjects: 25
Study: 35963296

Group type: EXPERIMENTAL
Intervention: Diaphragmatic Thickness (DT) in infants with BPD
Number of subjects: 111

Group type: COMPARATOR
Intervention: Diaphragmatic Thickness (DT) in healthy control participants
Number of subjects: 111
Study: 35963480

Group type: EXPERIMENTAL
Intervention: FOLFOX-based adjuvant chemotherapy
Number of subjects: 1532

Group type: EXPERIMENTAL
Intervention: TIL densities
Number of subjects: 1532
Study: 35963523

Group type: EXPERIMENTAL
Intervention: Guardant360 CDx
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oncomine Dx Target Test (ODxT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: CHRYSALIS study
Number of subjects: 81
Study: 35963650

Group type: EXPERIMENTAL
Intervention: Imperial RAPID risk score (five-item)
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: Imperial RAPID risk score (eight-item)
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: RAPID risk score
Number of subjects: 1189
Study: 35963665

Group type: EXPERIMENTAL
Intervention: Management of biliary acute pancreatitis according to evidence-based guidelines
Number of subjects: 5275

Group type: EXPERIMENTAL
Intervention: Optimal timing for the index CT scan
Number of subjects: 5275
Study: 35963741

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35963986

Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg once daily
Number of subjects: 60
Study: 35964087

Group type: EXPERIMENTAL
Intervention: 3-dimensional imaging assessment of wound surface area (WSA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clinician global assessment (CGA) of WSA
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Disease-related questionnaires and instruments (EBDASI, iscorEB)
Number of subjects: 30
Study: 35964116

Group type: EXPERIMENTAL
Intervention: Digital health intervention (mobile app) for 3 months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Usability assessment of the digital health solution
Number of subjects: 65
Study: 35964124

Group type: EXPERIMENTAL
Intervention: High Intensity (HI) group
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Low Intensity (LMI) group
Number of subjects: 577
Study: 35964141

Group type: EXPERIMENTAL
Intervention: Web-based computer-tailored physical activity intervention (ExerciseGuide UK)
Number of subjects: 35
Study: 35964151

Group type: EXPERIMENTAL
Intervention: Strategies to support attendance at initial mental health visits (details on specific strategies not provided)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Behavioral economics and implementation science frameworks applied to develop strategies
Number of subjects: 65
Study: 35964324

Group type: EXPERIMENTAL
Intervention: Systematic smoking cessation counselling (intervention phase)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Opportunistic smoking cessation counselling (observation phase)
Number of subjects: 458
Study: 35964548

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis for nausea and vomiting and proactive management of ILD/pneumonitis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Management strategies for T-DXd-related AEs (e.g. neutropenia, infusion-related reactions, alopecia, fatigue, left ventricular dysfunction)
Number of subjects: 0
Study: 35964555

Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Number of subjects: 27
Study: 35964609

Group type: EXPERIMENTAL
Intervention: Mitapivat (50 mg twice daily for 6 weeks, then 100 mg twice daily for 18 weeks)
Number of subjects: 20
Study: 35964683

Group type: EXPERIMENTAL
Intervention: EUS-guided through-the-needle-biopsy (TTNB) sampling with next-generation sequencing (NGS) for molecular analysis
Number of subjects: 101
Study: 35964847

Group type: EXPERIMENTAL
Intervention: Preprocedural CCTA
Number of subjects: 7034

Group type: COMPARATOR
Intervention: No preprocedural CCTA
Number of subjects: 7034
Study: 35965248

Group type: EXPERIMENTAL
Intervention: High stress hyperglycemia ratio (SHR) ≥1.24 in DM; ≥1.14 in non-DM
Number of subjects: 2089

Group type: EXPERIMENTAL
Intervention: Incorporation of SHR into the GRACE score
Number of subjects: 2089
Study: 35965389

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 507

Group type: COMPARATOR
Intervention: Baseline characteristics
Number of subjects: 507
Study: 35965432

Group type: EXPERIMENTAL
Intervention: Darigabat (0.3-10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (3 and 10 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle (PO)
Number of subjects: 0
Study: 35965534

Group type: EXPERIMENTAL
Intervention: Low-coverage whole-genome sequencing (LC-WGS) and whole-exome sequencing (WES) of plasma samples.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tumor genomic analysis (mutation and copy number alteration profiles).
Number of subjects: 24
Study: 35965642

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 0
Study: 35966482

Group type: EXPERIMENTAL
Intervention: Phase-oriented trauma treatment for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35966519

Group type: EXPERIMENTAL
Intervention: History of preeclampsia
Number of subjects: 1217

Group type: COMPARATOR
Intervention: History of normotensive pregnancies
Number of subjects: 1217
Study: 35966524

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 98
Study: 35966561

Group type: EXPERIMENTAL
Intervention: TAV-in-TAVR with a second supra-annular self-expanding (S-SE) TAVR
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: TAV-in-TAVR
Number of subjects: 155
Study: 35966841

Group type: EXPERIMENTAL
Intervention: Ultrasound phenotype assessment of septic cardiomyopathy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal cardiac ultrasound phenotypes
Number of subjects: 0
Study: 35967368

Group type: EXPERIMENTAL
Intervention: mRNA-1273
Number of subjects: 1867

Group type: COMPARATOR
Intervention: BNT162b2
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Gam-COVID-Vac
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: ChAdOx1-S
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Coronavac
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Ad5-nCoV
Number of subjects: 1867

Group type: EXPERIMENTAL
Intervention: Ad26.COV2
Number of subjects: 1867
Study: 35967617

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 60
Study: 35967820

Group type: EXPERIMENTAL
Intervention: OEA (oleoylethanolamide) daily for 16 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo daily for 16 months
Number of subjects: 100
Study: 35967922

Group type: EXPERIMENTAL
Intervention: Peer-delivered cognitive-behavioral stress management intervention
Number of subjects: 103

Group type: COMPARATOR
Intervention: Delayed intervention group (control)
Number of subjects: 103
Study: 35968303

Group type: EXPERIMENTAL
Intervention: Stroke patients with hypertension
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Contact with health care providers prior to stroke onset
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Antihypertensive medication use
Number of subjects: 869
Study: 35968314

Group type: EXPERIMENTAL
Intervention: Polish version of the Alberta Infant Motor Scale (AIMS)
Number of subjects: 145
Study: 35968440

Group type: EXPERIMENTAL
Intervention: Neuraxial labor analgesia
Number of subjects: 387

Group type: COMPARATOR
Intervention: No neuraxial labor analgesia (Control)
Number of subjects: 387
Study: 35968672

Group type: EXPERIMENTAL
Intervention: Twin Block appliance with a check-up every sixth week
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Twin Block appliance with a check-up every fourth week
Number of subjects: 73

Group type: COMPARATOR
Intervention: Twin Block appliance (both groups)
Number of subjects: 73
Study: 35968995

Group type: EXPERIMENTAL
Intervention: Severe-injury group (87 biopsies)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Late-injury group (221 biopsies)
Number of subjects: 645

Group type: COMPARATOR
Intervention: No-injury group (376 biopsies)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Mild-injury group (526 biopsies)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Moderate-injury group (110 biopsies)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: T cell-mediated rejection
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Early antibody-mediated rejection (AMR)
Number of subjects: 645

Group type: EXPERIMENTAL
Intervention: Late antibody-mediated rejection (AMR)
Number of subjects: 645
Study: 35969113

Group type: EXPERIMENTAL
Intervention: Milk oral immunotherapy (OIT)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Low-milk dose group
Number of subjects: 286

Group type: COMPARATOR
Intervention: Avoidance group
Number of subjects: 286
Study: 35969233

Group type: EXPERIMENTAL
Intervention: anti-PD-1 plus anti-lymphocyte activation gene 3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: autologous CD8+ tumor-infiltrating lymphocytes (TIL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD4+ TILs
Number of subjects: 0
Study: 35969416

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35969439

Group type: EXPERIMENTAL
Intervention: Noom Healthy Weight Program
Number of subjects: 600

Group type: COMPARATOR
Intervention: Noom Healthy Weight Control
Number of subjects: 600
Study: 35969451

Group type: EXPERIMENTAL
Intervention: C@nnected group videoconferencing intervention (4 sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (treatment as usual + educational brochures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C@nnected group videoconferencing intervention
Number of subjects: 0
Study: 35969452

Group type: EXPERIMENTAL
Intervention: Intervention group (active enrollment and teaching how to use the EPP)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (information on how to enroll in EPP in discharge paperwork)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intervention group (EPP use)
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Intervention group (EPP use and follow-up)
Number of subjects: 229
Study: 35969830

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab 240 mg once every two weeks ×6 and ipilimumab 1 mg/kg once every six weeks ×2, followed by adjuvant nivolumab 480 mg once every four weeks (nine injections)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab and ipilimumab
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Adjuvant nivolumab
Number of subjects: 32
Study: 35970164

Group type: EXPERIMENTAL
Intervention: Cochlear Implantation (CI)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control (no cochlear implant)
Number of subjects: 97
Study: 35970439

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 35970714

Group type: EXPERIMENTAL
Intervention: Alpha-1 MP (60 mg/kg) weekly for 52 weeks
Number of subjects: 0
Study: 35970920

Group type: EXPERIMENTAL
Intervention: Individualized, heterologous chimpanzee adenovirus (ChAd68) and self-amplifying mRNA (samRNA)-based neoantigen vaccine in combination with nivolumab and ipilimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab
Number of subjects: 0
Study: 35970951

Group type: EXPERIMENTAL
Intervention: Left bundle branch area pacing (LBBAP) lead connected to a dual-chamber DF-1 ICD
Number of subjects: 10

Group type: COMPARATOR
Intervention: Conventional RV sensing configuration
Number of subjects: 10
Study: 35971017

Group type: EXPERIMENTAL
Intervention: 1565-nm non-ablative fractional laser (NAFL)
Number of subjects: 18

Group type: COMPARATOR
Intervention: long-pulsed 1064-nm Nd:YAG laser (LPNY)
Number of subjects: 18
Study: 35971031

Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for myocardial blood flow (MBF) quantification
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for myocardial flow reserve (MFR) quantification
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for stress MBF
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT for MFR
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: NaI(Tl) SPECT
Number of subjects: 154

Group type: COMPARATOR
Intervention: MPI (myocardial perfusion imaging)
Number of subjects: 154
Study: 35971064

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided esophageal compression during pressure-controlled face-mask ventilation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided esophageal compression
Number of subjects: 42
Study: 35971072

Group type: EXPERIMENTAL
Intervention: OptiBP™ (smartphone application)
Number of subjects: 30
Study: 35971173

Group type: EXPERIMENTAL
Intervention: COPD patients undergoing primary PCI
Number of subjects: 15686

Group type: COMPARATOR
Intervention: Non-COPD patients undergoing primary PCI
Number of subjects: 15686
Study: 35971243

Group type: EXPERIMENTAL
Intervention: Corrective surgery (O)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No corrective surgery (NO)
Number of subjects: 27
Study: 35971307

Group type: EXPERIMENTAL
Intervention: Individually tailored rehabilitation program for 8 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Baseline assessment during modified tilt-test
Number of subjects: 37

Group type: COMPARATOR
Intervention: Second assessment during modified tilt-test after rehabilitation
Number of subjects: 37
Study: 35971416

Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 231
Study: 35971681

Group type: EXPERIMENTAL
Intervention: Smartphone-based automated insulin delivery (AID) using interoperable artificial pancreas system (iAPS) and zone model predictive control (MPC) on an unlocked smartphone for 48 hours.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Smartphone-based automated insulin delivery (AID)
Number of subjects: 20
Study: 35971857

Group type: EXPERIMENTAL
Intervention: Degarelix administration
Number of subjects: 29
Study: 35971900

Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence in 2017
Number of subjects: 19875

Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence in 2019
Number of subjects: 19875

Group type: EXPERIMENTAL
Intervention: H. pylori infection prevalence in all age groups in 2017
Number of subjects: 19875
Study: 35971951

Group type: EXPERIMENTAL
Intervention: Bepirovirsen (75-450 mg single dose; 150-450 mg multiple doses on days 1, 4, 8, 11, 15, and 22)
Number of subjects: 96
Study: 35972222

Group type: EXPERIMENTAL
Intervention: Estimated time in range (eTIR) adjusted for HbA1c and covariates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 0
Study: 35972355

Group type: EXPERIMENTAL
Intervention: High-risk plaque (HRP) attributes at CCTA defined high disease burden (plaque burden, ≥70%; minimum lumen area, <4 mm²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractional flow reserve (FFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resting distal coronary artery pressure (Pd)-to-aortic pressure (Pa) ratio (Pd/Pa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hyperemic flow (1/hyperemic mean transit time [Tmn])
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resting flow (1/resting Tmn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance (IMR)
Number of subjects: 0
Study: 35972454

Group type: EXPERIMENTAL
Intervention: High perceived stress (>50th percentile) during peri-implantation or early pregnancy
Number of subjects: 797

Group type: COMPARATOR
Intervention: Low perceived stress (≤50th percentile) during peri-implantation or early pregnancy
Number of subjects: 797
Study: 35972459

Group type: EXPERIMENTAL
Intervention: Secondary PVD
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Primary PVD
Number of subjects: 208